ALBERT

Description: Cyclophosphamide is one of several clinically important cancer drugs whose therapeutic efficacy is due in part to their ability to stimulate antitumor immune responses. Studying mouse models, we demonstrate that cyclophosphamide alters the composition of microbiota in the small intestine and induces the translocation of selected species of Gram-positive bacteria into secondary lymphoid organs. There, these bacteria stimulate the generation of a specific subset of "pathogenic" T helper 17 (pT(H)17) cells and memory T(H)1 immune responses. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram-positive bacteria showed a reduction in pT(H)17 responses, and their tumors were resistant to cyclophosphamide. Adoptive transfer of pT(H)17 cells partially restored the antitumor efficacy of cyclophosphamide. These results suggest that the gut microbiota help shape the anticancer immune response.〈br /〉〈br /〉〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048947/" target="_blank"〉〈img src="https://static.pubmed.gov/portal/portal3rc.fcgi/4089621/img/3977009" border="0"〉〈/a〉   〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048947/" target="_blank"〉This paper as free author manuscript - peer-reviewed and accepted for publication〈/a〉〈br /〉〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Viaud, Sophie -- Saccheri, Fabiana -- Mignot, Gregoire -- Yamazaki, Takahiro -- Daillere, Romain -- Hannani, Dalil -- Enot, David P -- Pfirschke, Christina -- Engblom, Camilla -- Pittet, Mikael J -- Schlitzer, Andreas -- Ginhoux, Florent -- Apetoh, Lionel -- Chachaty, Elisabeth -- Woerther, Paul-Louis -- Eberl, Gerard -- Berard, Marion -- Ecobichon, Chantal -- Clermont, Dominique -- Bizet, Chantal -- Gaboriau-Routhiau, Valerie -- Cerf-Bensussan, Nadine -- Opolon, Paule -- Yessaad, Nadia -- Vivier, Eric -- Ryffel, Bernhard -- Elson, Charles O -- Dore, Joel -- Kroemer, Guido -- Lepage, Patricia -- Boneca, Ivo Gomperts -- Ghiringhelli, Francois -- Zitvogel, Laurence -- P01 DK071176/DK/NIDDK NIH HHS/ -- P01DK071176/DK/NIDDK NIH HHS/ -- P50 CA086355/CA/NCI NIH HHS/ -- R01 AI084880/AI/NIAID NIH HHS/ -- New York, N.Y. -- Science. 2013 Nov 22;342(6161):971-6. doi: 10.1126/science.1240537.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Institut National de la Sante et de la Recherche Medicale, U1015, Equipe labellisee Ligue Nationale Contre le Cancer, Institut Gustave Roussy, Villejuif, France.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/24264990" target="_blank"〉PubMed〈/a〉

Description: Antitumor immunity driven by intratumoral dendritic cells contributes to the efficacy of anthracycline-based chemotherapy in cancer. We identified a loss-of-function allele of the gene coding for formyl peptide receptor 1 (FPR1) that was associated with poor metastasis-free and overall survival in breast and colorectal cancer patients receiving adjuvant chemotherapy. The therapeutic effects of anthracyclines were abrogated in tumor-bearing Fpr1(-/-) mice due to impaired antitumor immunity. Fpr1-deficient dendritic cells failed to approach dying cancer cells and, as a result, could not elicit antitumor T cell immunity. Experiments performed in a microfluidic device confirmed that FPR1 and its ligand, annexin-1, promoted stable interactions between dying cancer cells and human or murine leukocytes. Altogether, these results highlight the importance of FPR1 in chemotherapy-induced anticancer immune responses.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Vacchelli, Erika -- Ma, Yuting -- Baracco, Elisa E -- Sistigu, Antonella -- Enot, David P -- Pietrocola, Federico -- Yang, Heng -- Adjemian, Sandy -- Chaba, Kariman -- Semeraro, Michaela -- Signore, Michele -- De Ninno, Adele -- Lucarini, Valeria -- Peschiaroli, Francesca -- Businaro, Luca -- Gerardino, Annamaria -- Manic, Gwenola -- Ulas, Thomas -- Gunther, Patrick -- Schultze, Joachim L -- Kepp, Oliver -- Stoll, Gautier -- Lefebvre, Celine -- Mulot, Claire -- Castoldi, Francesca -- Rusakiewicz, Sylvie -- Ladoire, Sylvain -- Apetoh, Lionel -- Bravo-San Pedro, Jose Manuel -- Lucattelli, Monica -- Delarasse, Cecile -- Boige, Valerie -- Ducreux, Michel -- Delaloge, Suzette -- Borg, Christophe -- Andre, Fabrice -- Schiavoni, Giovanna -- Vitale, Ilio -- Laurent-Puig, Pierre -- Mattei, Fabrizio -- Zitvogel, Laurence -- Kroemer, Guido -- New York, N.Y. -- Science. 2015 Nov 20;350(6263):972-8. doi: 10.1126/science.aad0779. Epub 2015 Oct 29.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Equipe 11 Labellisee par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Universite Paris Descartes, Sorbonne Paris Cite, Paris, France. Universite Pierre et Marie Curie, Paris, France. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Equipe 11 Labellisee par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Universite Paris Descartes, Sorbonne Paris Cite, Paris, France. Universite Pierre et Marie Curie, Paris, France. Suzhou Institute of Systems Medicine, Suzhou, Jiangsu, China. Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Equipe 11 Labellisee par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Faculte de Medecine, Universite Paris-Saclay, Kremlin-Bicetre, France. ; Regina Elena National Cancer Institute, Rome, Italy. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Equipe 11 Labellisee par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Equipe 11 Labellisee par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Equipe 11 Labellisee par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Universite Paris Descartes, Sorbonne Paris Cite, Paris, France. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1015, Villejuif, France. Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France. ; Department of Hematology, Oncology, and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy. ; Italian National Research Council, Institute for Photonics and Nanotechnology, Rome, Italy. ; Genomics and Immunoregulation, Life and Medical Science Center Institute, University of Bonn, Germany. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U981, Villejuif, France. ; Universite Paris Sorbonne Cite, UMRS 775, INSERM, Paris, France. INSERM U1147, Centre de Ressources Biologiques (CRB) EPIGENETIC, Paris, France. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Equipe 11 Labellisee par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Faculte de Medecine, Universite Paris-Saclay, Kremlin-Bicetre, France. Sotio, Prague, Czech Republic. ; Department of Medical Oncology, Centre Georges-Francois Leclerc, Dijon, France. Universite Bourgogne Franche-Comte, Dijon, France. Centre Georges Francois Leclerc, Dijon, France. ; Department of Life Sciences, University of Siena, Siena, Italy. ; Institut du Cerveau et de la Moelle Epiniere, ICM CNRS UMR 7225 - INSERM U 1127 - UPMC-P6 UMR S 1127, Equipe Neurogenetique et Physiologie Hopital de la Pitie-Salpetriere, 47, Boulevard de l'Hopital, 75013 Paris, France. ; INSERM U1147, Centre de Ressources Biologiques (CRB) EPIGENETIC, Paris, France. Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif Cedex, France. ; Faculte de Medecine, Universite Paris-Saclay, Kremlin-Bicetre, France. Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif Cedex, France. ; INSERM, U981, Villejuif, France. Department of Breast Oncology, Gustave Roussy Cancer Campus, Villejuif, France. ; University of Franche-Comte, INSERM 1098, France. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U981, Villejuif, France. Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France. Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. ; Regina Elena National Cancer Institute, Rome, Italy. Department of Biology, University of Rome "Tor Vergata," Rome, Italy. ; Universite Paris Sorbonne Cite, UMRS 775, INSERM, Paris, France. INSERM U1147, Centre de Ressources Biologiques (CRB) EPIGENETIC, Paris, France. Pole de Biologie, Hopital Europeen Georges Pompidou, AP-HP, Paris, France. ; Gustave Roussy Cancer Campus, Villejuif, France. Faculte de Medecine, Universite Paris-Saclay, Kremlin-Bicetre, France. INSERM, U1015, Villejuif, France. Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France. kroemer@orange.fr laurence.zitvogel@gustaveroussy.fr. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Equipe 11 Labellisee par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Universite Paris Descartes, Sorbonne Paris Cite, Paris, France. Universite Pierre et Marie Curie, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France. Pole de Biologie, Hopital Europeen Georges Pompidou, AP-HP, Paris, France. Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, 17176 Stockholm, Sweden. kroemer@orange.fr laurence.zitvogel@gustaveroussy.fr.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/26516201" target="_blank"〉PubMed〈/a〉

Description: IL-27–induced type 1 regulatory T (Tr1) cells suppress autoimmunity by producing IL-10. Signal transducer and activator of transcription (STAT) 1 and STAT3 have been described as key transcription factors that promote IL-10 secretion from Tr1 cells induced by IL-27. However, the molecular pathways for negatively regulating Tr1 cell differentiation remain...